TY - JOUR
T1 - The role of optical coherence tomography and infrared oculography in assessing the visual pathway and CNS in multiple sclerosis
AU - Coric, Danko
AU - Nij Bijvank, Jenny A.
AU - van Rijn, Laurentius J.
AU - Petzold, Axel
AU - Balk, Lisanne J.
PY - 2018
Y1 - 2018
N2 - In this review, a current overview is provided of how optical coherence tomography and infrared oculography can aid in assessing the visual system and CNS in multiple sclerosis (MS). Both afferent and efferent visual disorders are common in MS and visual complaints can have a tremendous impact on daily functioning. Optical coherence tomography and infrared oculography can detect and quantify visual disorders with high accuracy, but could also serve as quantitative markers for inflammation, neurodegeneration and network changes including cognitive decline in MS patients. The assessment of the efferent and afferent visual pathways is relevant for monitoring and predicting the disease course, but is also potentially valuable as an outcome measure in therapeutic trials.
AB - In this review, a current overview is provided of how optical coherence tomography and infrared oculography can aid in assessing the visual system and CNS in multiple sclerosis (MS). Both afferent and efferent visual disorders are common in MS and visual complaints can have a tremendous impact on daily functioning. Optical coherence tomography and infrared oculography can detect and quantify visual disorders with high accuracy, but could also serve as quantitative markers for inflammation, neurodegeneration and network changes including cognitive decline in MS patients. The assessment of the efferent and afferent visual pathways is relevant for monitoring and predicting the disease course, but is also potentially valuable as an outcome measure in therapeutic trials.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85058724485&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30226111
U2 - https://doi.org/10.2217/nmt-2018-0011
DO - https://doi.org/10.2217/nmt-2018-0011
M3 - Article
C2 - 30226111
SN - 1758-2024
VL - 8
SP - 323
EP - 335
JO - Neurodegenerative Disease Management
JF - Neurodegenerative Disease Management
IS - 5
ER -